Chrissy Metz discloses GLP-1 use and becomes an ambassador for Ro
Metz says perimenopause led her to try a GLP-1 after years of doubt, and she is now a brand ambassador for Ro, which sells weight loss treatment.
Actress Chrissy Metz says she has started taking a GLP-1 medication after years of assuming the drugs would not help her, and she has taken on an ambassador role with Ro, a telehealth company that sells weight loss treatment, according to an Everyday Health roundup of celebrity GLP-1 disclosures that cites her interview with People [1].
Metz, 45, told People that entering perimenopause pushed her to reconsider. She pointed to obesity in her family and her father's history, and said she had already gone through dieting and therapy without lasting results [1]. "I'm not getting any younger," she said [1].
She described a change in how she thinks about eating, saying she is no longer consumed by what her next meal will be, and that the medication has helped her move more easily and has reduced joint pain and inflammation [1]. She said she had treated food as something bad for years because that is what she was taught [1].
A caption accompanying her entry in the roundup states that Metz lost 100 pounds on a GLP-1 [1]. Which drug she takes, the dose, how long she has been on it and whether she is still taking it have not been reported [1]. Her account includes no starting weight and no timeline [1].
Whether the Ro arrangement is paid is not disclosed [1]. The same article describes tennis player Serena Williams as a paid Ro ambassador who has said she lost 31 pounds using Zepbound (tirzepatide) after her second pregnancy, and who has argued that using a weight loss drug "isn't a shortcut, it's healthcare" and is one part of a plan that also includes diet and exercise [1].
Metz is one of several public figures in the roundup. Oprah Winfrey has said she regained about 20 pounds over 12 months after stopping her GLP-1 to test whether she could hold her weight without it, and now calls the medication "a lifetime thing" [1]. Shaquille O'Neal said in June 2026 that he takes Zepbound for moderate obstructive sleep apnea [1]. Kathy Bates has said she lost 100 pounds over seven years, the last 20 with Ozempic (semaglutide), after a type 2 diabetes diagnosis [1]. Charles Barkley said he went from 352 pounds to 290 on Mounjaro (tirzepatide) [1].
Why it matters for patients
Metz's disclosure arrives in the middle of a public argument about weight, appearance and who these medications are for. The article carries no response from body-positivity advocates and no comment from Metz about how the ambassador role fits with her public identity, so that reaction has not been reported [1].
Two different things are happening at once: a patient describing her own treatment, and a commercial relationship with a company that sells access to that class of drugs. The terms of Metz's role are not disclosed, while the article identifies Williams's deal as paid [1].
The specific molecule matters, because the drugs named in the roundup are not interchangeable: Ozempic, Wegovy and Rybelsus are semaglutide, while Zepbound and Mounjaro are tirzepatide [1]. Metz has not said which one she uses [1]. Nothing in the article reports what she pays, whether insurance covers it or who prescribed it, and one person's experience does not predict how a medication will work for someone else.
What happens next
No follow-up milestones have been reported. The roundup carrying Metz's comments was updated August 11, 2026, and the caption with her entry is dated August 10, 2026 [1]. Ro has not publicly described the terms of the partnership, and no information about her dose, duration of treatment or clinical results beyond the caption has been released [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.